Taysha Gene Therapies, Inc.TSHA stock score: 47/100
$3.77 · -5.51% · Scored Nov 19, 2026
- Technical
- 33
- Fundamental
- 51
- News
- 55
The reading
Taysha Gene Therapies (TSHA) scores 47 out of 100, which reads weak, higher than 41% of Healthcare stocks and 39% of the 4,118 US stocks we score.
The composite weights fundamentals 80% and technicals 20%: fundamentals read 51, technicals 33.
Among the fundamentals, Quick Ratio at 100 and Price Target at 100 score highest, while Earnings Profitability (Quarterly) at 0 weighs the most against it.
On the daily chart, trend-following indicators average 21 and contrarian oscillators 64 — a split worth reading before trusting the technical total.
News sentiment is neutral at 55; it is shown, not counted in the composite.
Since Aug 23, 2026 the composite has ranged from 37 to 51, and it is down 4 points over the period.
About Taysha Gene Therapies
Taysha Gene Therapies (TSHA) is a Dallas-based clinical-stage biotechnology company developing gene therapies for severe genetic disorders of the central nervous system. Its lead candidate, TSHA-102, is designed to treat Rett syndrome, a rare neurodevelopmental disorder that mainly affects girls and is caused by mutations in the MECP2 gene. The one-time therapy uses an adeno-associated virus to deliver a shortened version of the MECP2 gene directly into the spinal fluid, with a built-in control mechanism meant to keep gene expression in a safe range. TSHA-102 has Breakthrough Therapy designation from the FDA, and the company is running a pivotal trial designed to support a marketing application, along with manufacturing work to prepare for commercial supply. Taysha has no product revenue and funds development with cash raised from investors.
In Rett syndrome, Taysha competes with Acadia Pharmaceuticals, which sells Daybue, a drug that treats symptoms, and with Neurogene, which is developing another gene therapy. Its edge rests on a potential one-time treatment that addresses the underlying genetic cause, clinical data across a range of ages and a regulatory designation that brings closer FDA engagement. Investors who follow TSHA stock tend to watch data from its pivotal trial and progress toward a marketing application. Safety findings and manufacturing readiness are closely followed. Cash runway, launch planning and potential expansion into other conditions are other factors.
What’s driving the score
The strongest and weakest of the scorers that count toward TSHA’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.
Fundamental
51Pulling it up
- Quick Ratio100
Quick ratio measures a company's ability to meet short-term obligations with liquid assets.
- Price Target100
Price target score compares the current stock price to analyst consensus targets.
Current assets divided by current liabilities: the ability to pay short-term bills.
Holding it back
Earnings Profitability (Quarterly) measures recent profitability using trailing 12-month quarterly data.
Absolute profitability: whether the company is profitable, its net margin against the sector range, and how consistently it has been profitable over three years.
EV/Revenue compares the whole company's value, debt included, with its sales.
37 weighted scorers; 2 had no data today and are left out rather than counted as zero.
Technical · daily
25Pulling it up
Bollinger Bands (20-period) plot standard deviations above and below a moving average.
Bollinger Bands (50-period) measure where price sits between bands two standard deviations around its 50-period average.
Know Sure Thing (KST) combines multiple rate-of-change calculations to identify long-term trend reversals.
Holding it back
Candlestick patterns recognize specific price formations that historically suggest continuation or reversal.
Simple Moving Average (100-period) provides a longer-term perspective on price trends.
- VWAP0
Volume Weighted Average Price (VWAP) shows the average price weighted by volume.
62 weighted scorers; 3 had no data today and are left out rather than counted as zero.
News · shown, not counted
- Global News
- 55
Technical score by timeframe
| Chart | Score | Weight |
|---|---|---|
| Hourly | 32 | 1 |
| Daily | 25 | 3 |
| Weekly | 29 | 2 |
| Monthly | 48 | 2 |
Composite score, last 90 days
Show the daily numbers
| Date | Composite |
|---|---|
| Nov 19, 2026 | 47 |
| Nov 18, 2026 | 48 |
| Nov 17, 2026 | 48 |
| Nov 16, 2026 | 48 |
| Nov 15, 2026 | 49 |
| Nov 14, 2026 | 49 |
| Nov 13, 2026 | 49 |
| Nov 12, 2026 | 45 |
| Nov 11, 2026 | 43 |
| Nov 10, 2026 | 43 |
| Nov 8, 2026 | 43 |
| Nov 7, 2026 | 43 |
| Nov 6, 2026 | 43 |
| Nov 5, 2026 | 41 |
| Nov 4, 2026 | 43 |
| Nov 3, 2026 | 41 |
| Nov 2, 2026 | 40 |
| Nov 1, 2026 | 43 |
| Oct 30, 2026 | 42 |
| Oct 29, 2026 | 42 |
| Oct 28, 2026 | 42 |
| Oct 27, 2026 | 42 |
| Oct 26, 2026 | 40 |
| Oct 25, 2026 | 40 |
| Oct 24, 2026 | 40 |
| Oct 23, 2026 | 39 |
| Oct 22, 2026 | 40 |
| Oct 21, 2026 | 41 |
| Oct 20, 2026 | 41 |
| Oct 19, 2026 | 40 |
| Oct 18, 2026 | 38 |
| Oct 17, 2026 | 38 |
| Oct 16, 2026 | 38 |
| Oct 15, 2026 | 37 |
| Oct 14, 2026 | 37 |
| Oct 13, 2026 | 37 |
| Oct 12, 2026 | 39 |
| Oct 11, 2026 | 41 |
| Oct 10, 2026 | 41 |
| Oct 9, 2026 | 41 |
| Oct 8, 2026 | 41 |
| Oct 7, 2026 | 40 |
| Oct 6, 2026 | 40 |
| Oct 5, 2026 | 41 |
| Oct 4, 2026 | 41 |
| Oct 3, 2026 | 41 |
| Oct 2, 2026 | 41 |
| Oct 1, 2026 | 42 |
| Sep 30, 2026 | 45 |
| Sep 29, 2026 | 45 |
| Sep 28, 2026 | 45 |
| Sep 27, 2026 | 43 |
| Sep 26, 2026 | 43 |
| Sep 25, 2026 | 43 |
| Sep 24, 2026 | 44 |
| Sep 23, 2026 | 45 |
| Sep 22, 2026 | 47 |
| Sep 21, 2026 | 45 |
| Sep 20, 2026 | 45 |
| Sep 19, 2026 | 45 |
| Sep 18, 2026 | 45 |
| Sep 17, 2026 | 47 |
| Sep 16, 2026 | 44 |
| Sep 15, 2026 | 44 |
| Sep 14, 2026 | 45 |
| Sep 13, 2026 | 45 |
| Sep 12, 2026 | 45 |
| Sep 11, 2026 | 45 |
| Sep 10, 2026 | 45 |
| Sep 9, 2026 | 46 |
| Sep 8, 2026 | 49 |
| Sep 7, 2026 | 49 |
| Sep 6, 2026 | 49 |
| Sep 5, 2026 | 49 |
| Sep 4, 2026 | 48 |
| Sep 3, 2026 | 47 |
| Sep 2, 2026 | 48 |
| Sep 1, 2026 | 50 |
| Aug 31, 2026 | 48 |
| Aug 30, 2026 | 49 |
| Aug 29, 2026 | 49 |
| Aug 28, 2026 | 48 |
| Aug 27, 2026 | 49 |
| Aug 26, 2026 | 50 |
| Aug 25, 2026 | 51 |
| Aug 24, 2026 | 50 |
| Aug 23, 2026 | 51 |
Key facts
- Market cap
- $1.2B
- Sector
- Healthcare
- Industry
- Biotechnology
- Beta
- 1.31
- Risk grade (1–10)
- 10
- Next earnings
- Nov 12, 2026
Biotechnology peers
| Company | Market cap | Score |
|---|---|---|
| GHRS GH Research | $1.3B | 42 |
| NVAX Novavax | $1.3B | 55 |
| MNKD MannKind | $1.3B | 56 |
| MLYS Mineralys Therapeutics | $1.3B | 31 |
| SLN Silence Therapeutics | $1.2B | 55 |
| GPCR Structure Therapeutics | $1.2B | 29 |
Questions
What is TSHA's stock rating today?
TSHA scores 47/100 (Weak) as of Nov 19, 2026: technical 33, fundamental 51, and news sentiment 55, which is shown but not counted. Scores are recomputed every night.
What does Taysha Gene Therapies do?
Taysha Gene Therapies (TSHA) is a Dallas-based clinical-stage biotechnology company developing gene therapies for severe genetic disorders of the central nervous system. Its lead candidate, TSHA-102, is designed to treat Rett syndrome, a rare neurodevelopmental disorder that mainly affects girls and is caused by mutations in the MECP2 gene.
Is TSHA stock a buy?
The score is not a buy or sell recommendation. A 47 says the technical and fundamental signals we measure lean weak today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.
How is the TSHA score calculated?
99 weighted scorers feed it today: 37 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 4 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.
Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.
Embed this score
A badge for a blog post, newsletter or README. It updates every night and links back here. More badges
HTML
<a href="https://stocksscores.com/stocks/tsha/"><img src="https://stocksscores.com/stocks/tsha/badge.svg" alt="TSHA stock score" height="20"></a>
Markdown
[](https://stocksscores.com/stocks/tsha/)